HSV-1-mediated NGF delivery delays nociceptive deficits in a genetic model of diabetic neuropathy
- 31 March 2006
- journal article
- research article
- Published by Elsevier in Experimental Neurology
- Vol. 198 (1) , 260-270
- https://doi.org/10.1016/j.expneurol.2005.12.006
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Nerve growth factor for the treatment of diabetic neuropathy: What went wrong, what went right, and what does the future hold?Published by Elsevier ,2002
- Neurotrophic factors and neuropathic painCurrent Opinion in Pharmacology, 2001
- GDNF Rescues Nonpeptidergic Unmyelinated Primary Afferents in Streptozotocin-Treated Diabetic MiceExperimental Neurology, 2001
- Efficacy and Safety of Recombinant Human Nerve Growth Factor in Patients With Diabetic PolyneuropathyJAMA, 2000
- Neurotrophic factors in the therapy of diabetic neuropathyThe American Journal of Medicine, 1999
- Recombinant human nerve growth factor in the treatment of diabetic polyneuropathyNeurology, 1998
- NGF has opposing effects on Na+ channel III and SNS gene expression in spinal sensory neuronsNeuroReport, 1997
- The Clinical Spectrum of Diabetic NeuropathySeminars in Neurology, 1996
- Neurotrophins and peripheral neuropathyPhilosophical Transactions Of The Royal Society B-Biological Sciences, 1996
- Nerve growth factor administration protects against experimental diabetic sensory neuropathyBrain Research, 1994